SOX2 and non-small cell lung carcinoma: Following treatment of NSCLC with the EGFR inhibitor erlotinib, SOX2 expression was reported to be higher in NSCLC harboring EGFR mutations than in controls and more likely such tumors could develop resistance to the drug by repressing pro-apoptotic BH3-only genes, such as BIM and BMF.